Emyria S3 CBD trial ‘on hold’ as firm stresses need to focus on revenue by Steve Jones February 7, 2024February 7, 2024 Emyria has said it must focus on revenue generation rather than registering a low-dose CBD product […]
Financial results: Bod Science; Zelira Therapeutics; Emyria; Epsilon Healthcare; Elixinol; MGC Pharma by Steve Jones August 1, 2023April 30, 2024
Emyria shares take a hit as company raises another A$2.5 million by Steve Jones May 1, 2023April 30, 2024
Emyria eyes US market with launch of high-dose CBD capsule by Steve Jones April 24, 2023April 30, 2024
